UPC (Universe Pharmaceuticals) Debt-to-Asset : 0.13 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Universe Pharmaceuticals Debt-to-Asset?

Universe Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.43 Mil. Universe Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.08 Mil. Universe Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $49.43 Mil. Universe Pharmaceuticals's debt to asset for the quarter that ended in Mar. 2024 was 0.13.

Universe Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Universe Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universe Pharmaceuticals Debt-to-Asset Chart

Universe Pharmaceuticals Annual Data

Trend

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-Asset

Get a 7-Day Free Trial

0.14

0.09

0.06

0.07

0.10

Universe Pharmaceuticals Semi-Annual Data
	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial							0.06	0.07	0.06	0.10	0.13

Competitive Comparison of Universe Pharmaceuticals's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universe Pharmaceuticals's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Universe Pharmaceuticals's Debt-to-Asset falls into.

Universe Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Universe Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.482	+	0)	/	53.287
	=	0.10

Universe Pharmaceuticals's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.432	+	2.077)	/	49.431
	=	0.13

Universe Pharmaceuticals (NAS:UPC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Universe Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Universe Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Universe Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Universe Pharmaceuticals Inc (NAS:UPC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

265 Jingjiu Avenue, Jinggangshan Economic & Technological Development Zone, Jiangxi, Ji’an, CHN, 343100

Website

http://www.universe-pharmacy.com

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.